Janux Therapeutics (JANX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Janux Therapeutics (JANX) over the past year, losing 12.5% versus a loss of 23.6%. Over five years, JANX leads with a -12.4% price change compared with -75.2% for TSHA. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.13 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | TSHA |
|---|---|---|
| Share price | $18.50 | $4.43 |
| Market cap | $1.13B | $1.44B |
| 1-day change | +3.24% | 0.00% |
| YTD return | +34.06% | -19.45% |
| 1-year return | -23.55% | -12.45% |
| 5-year return | -12.45% | -75.22% |
| EPS (TTM) | $-1.64 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $7.30 |
| 52-week low | $12.12 | $3.69 |
| Distance from 52-week high | -47.65% | -39.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +95.89% | +193.45% |
| Average volume | 845.95K | 3.28M |
| Shares outstanding | 61.14M | 325.83M |
| Employees | 113 | 99 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TSHA has outperformed JANX by 11.1 percentage points over the past year.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
JANX vs TSHA FAQ
Which is bigger, Janux Therapeutics or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.13B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or TSHA?
TSHA returned -12.45% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.